Local view for "https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/969"
| Predicate | Value (sorted: none) |
|---|
| rdf:type |
|
| rdf:type |
|
| rdfs:label |
|
| ?:Evidence_type |
|
| ?:Evidence_enzyme_system |
|
| dc:creator |
|
| dc:date |
|
| ?:content |
"Drug Interactions
In vitro drug metabolism studies suggest that there is a potential for drug interactions when trazodone is given with CYP3A4 inhibitors. Ritonavir, a potent CYP3A4 inhibitor, increased the Cmax, AUC, and elimination half-life, and decreased clearance of trazodone after administration of ritonavir twice daily for 2 days. Adverse effects including nausea, hypotension, and syncope were observed when ritonavir and trazodone were co-administered. It is likely that ketoconazole, indinavir, and other CYP3A4 inhibitors such as itraconazole or nefazodone may lead to substantial increases in trazodone plasma concentrations, with the potential for adverse effects. If trazodone is used with a potent CYP3A4 inhibitor, a lower dose of trazodone should be considered.
Carbamazepine reduced plasma concentrations of trazodone when co-administered. Patients should be closely monitored to see if there is a need for an increased dose of trazodone when taking both drugs."
|
| rdfs:seeAlso |
|
All properties reside in the graph file:///home/swish/src/ClioPatria/guidelines/dikb.ttl
The resource appears as object in one triple:
{ trazodone_is_not_substrate_of_cyp3a4, <http://purl.org/swan/1.2/swan-commons#citesAsRefutingEvidence>, evidence_1151 }
Context graph
